PMID- 38026603
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 17
DP  - 2023
TI  - Early Clinical Experience with a New Hydrophobic Acrylic Single-Piece Monofocal 
      Intraocular Lens.
PG  - 3419-3427
LID - 10.2147/OPTH.S433530 [doi]
AB  - PURPOSE: To evaluate early clinical outcomes and adverse events (AEs) in cataract 
      patients following implantation of a monofocal hydrophobic acrylic IOL with a new 
      optimized non-constant aberration-correcting design (CT LUCIA 621P). METHODS: 
      This retrospective study included patients with visually significant cataracts 
      who underwent implantation of the CT LUCIA 621P IOL. Refraction, corrected (CDVA) 
      and uncorrected (UDVA) visual acuity of the last available visit were used in the 
      analysis. Intraoperative and postoperative AEs of the cohort were reviewed. 
      RESULTS: A total of 191 eyes of 133 patients with the mean age of 70.2+/-11.2 years 
      were included in this study. The mean follow-up time of the last available visit 
      was 1.7+/-1.3 months. The mean postoperative monocular UDVA was 0.09+/-0.16 logMAR 
      ( approximately 20/25), and 74.9% (143/191) eyes achieved >/=20/25 UDVA. The percentage of eyes 
      with manifest spherical equivalent (MSE) within +/-0.50D and +/-1.00D of emmetropia 
      was 84.8% (162/191) and 98.4% (188/191), respectively. Linear regression of 
      attempted vs achieved MSE showed a tight relationship, with the coefficient of 
      determination close to 1 (R(2)=0.99), indicating a very predictable refractive 
      correction. The reported AEs were those typically expected after cataract 
      surgery. There were no AEs related to intraoperative manipulation with the 
      IOL/injector or to postoperative stability of the IOL in the capsular bag. No eye 
      lost >/=2 lines of CDVA. CONCLUSION: The implantation of CT LUCIA 621P resulted in 
      good refractive predictability and visual outcomes. No IOL-related adverse events 
      were reported.
CI  - (c) 2023 Schallhorn et al.
FAU - Schallhorn, Steven C
AU  - Schallhorn SC
AD  - Department of Ophthalmology, University of California, San Francisco, CA, USA.
AD  - Optical Express, Glasgow, UK.
AD  - Carl Zeiss Meditec, Inc, Dublin, CA, USA.
FAU - Teenan, David
AU  - Teenan D
AUID- ORCID: 0000-0001-5489-0828
AD  - Optical Express, Glasgow, UK.
FAU - Venter, Jan A
AU  - Venter JA
AD  - Optical Express, Glasgow, UK.
FAU - Schallhorn, Julie M
AU  - Schallhorn JM
AD  - Department of Ophthalmology, University of California, San Francisco, CA, USA.
AD  - F.I. Proctor Foundation, University of California, San Francisco, CA, USA.
FAU - Hannan, Stephen J
AU  - Hannan SJ
AD  - Optical Express, Glasgow, UK.
LA  - eng
PT  - Journal Article
DEP - 20231113
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC10655610
OTO - NOTNLM
OT  - cataract surgery
OT  - monofocal IOL
OT  - non-constant aberration-correcting optic design
COIS- Steven Schallhorn is a chief medical officer for Carl Zeiss Meditec and a 
      chairman of medical advisory board for Optical Express. Stephen Hannan, Jan 
      Venter, and David Teenan are employees of Optical Express. Julie Schallhorn 
      received personal fees from Carl Zeiss Meditec, Allergan, Long Bridge, and 
      Forsight V6 and has a financial interest in Journey 1, Neurotrigger, and Novus 
      Vision. The authors report no other conflicts of interest in this work.
EDAT- 2023/11/29 18:43
MHDA- 2023/11/29 18:44
PMCR- 2023/11/13
CRDT- 2023/11/29 16:55
PHST- 2023/08/02 00:00 [received]
PHST- 2023/10/05 00:00 [accepted]
PHST- 2023/11/29 18:44 [medline]
PHST- 2023/11/29 18:43 [pubmed]
PHST- 2023/11/29 16:55 [entrez]
PHST- 2023/11/13 00:00 [pmc-release]
AID - 433530 [pii]
AID - 10.2147/OPTH.S433530 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2023 Nov 13;17:3419-3427. doi: 10.2147/OPTH.S433530. eCollection 
      2023.